Clinical Trial Update: A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia A [Phase 1]

View source ↗

Summary

Phase 1 single-dose trial of NNC 0155-0000-0004 in patients with hemophilia A has completed; the study was sponsored by Novo Nordisk A/S.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• NNC 0155-0000-0004

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Haemophilia A | Phase 1 | Status: COMPLETED